We apply spatial metabolomics and K-means clustering method to identify metabolically distinct tumour subpopulations of HER2-positive advanced GC from routinely preserved pretherapeutic biopsies, and assess their relationships with the response to trastuzumab treatment. This evidence concerns the gene ERBB2 and neoplasm.